Literature DB >> 23011189

Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic Acid.

Bang-Bin Chen1, Chao-Yu Hsu, Chih-Wei Yu, Shwu-Yuan Wei, Jia-Horng Kao, Hsuan-Shu Lee, Tiffany Ting-Fang Shih.   

Abstract

PURPOSE: The aim of this study was to evaluate the serial signal changes in hepatobiliary enhancement on gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid or gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and its correlation with clinical parameters.
METHOD: Under institutional review board approval, Gd-EOB-DTPA-enhanced magnetic resonance imaging was performed in 77 subjects (21 healthy volunteers and 56 biopsy-proven chronic hepatitis patients), and the signal intensities of the liver and common hepatic ducts (CHD) were measured every 2 minutes up to 50 minutes postcontrast. The associations among hepatic and CHD signals, physiological and hematological variables, histological activity index, and Metavir scores were analyzed with Pearson correlation and multiple linear stepwise regressions. The predictive ability of contrast enhancement index (CEI) of the liver with histological activity index and fibrosis scores at different time points were studied using nonparametric receiver operating characteristic curves.
RESULTS: Among the clinical parameters, body weight and body mass index had the highest negative correlation with hepatobiliary enhancement between 2 and 50 minutes postcontrast (P < 0.001). Multiple regressions showed that creatinine level, body weight, and body mass index were independent predictors for both mean hepatic and CHD signal intensity (P < 0.05). Patients with more severe fibrosis or moderate necrosis tended to have lower CEIs than other patients were. The predictive ability of CEI for the best differentiation between no fibrosis and any fibrosis (F ≥ 1) was at 10 minutes postcontrast (area under the receiver operating characteristic curve, 0.797).
CONCLUSIONS: Delayed hepatobiliary enhancement with Gd-EOB-DTPA could be possibly used for staging liver fibrosis. Contrast enhancement index of the liver at 10 minutes is useful for differentiating between no fibrosis and any degree of fibrosis in chronic hepatitis patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011189     DOI: 10.1097/RLI.0b013e3182652fb9

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  5 in total

1.  Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Bang-Bin Chen; Takamichi Murakami; Tiffany Ting-Fang Shih; Michiie Sakamoto; Osamu Matsui; Byung-Ihn Choi; Myeong-Jin Kim; Jeong Min Lee; Ren-Jie Yang; Meng-Su Zeng; Ran-Chou Chen; Ja-Der Liang
Journal:  Liver Cancer       Date:  2015-10-15       Impact factor: 11.740

2.  Quantitative Assessment of Liver Function Using Gadoxetate-Enhanced Magnetic Resonance Imaging: Monitoring Transporter-Mediated Processes in Healthy Volunteers.

Authors:  Leonidas Georgiou; Jeffrey Penny; Glynis Nicholls; Neil Woodhouse; François-Xavier Blé; Penny L Hubbard Cristinacce; Josephine H Naish
Journal:  Invest Radiol       Date:  2017-02       Impact factor: 6.016

3.  Multiparametric radiomics nomogram may be used for predicting the severity of esophageal varices in cirrhotic patients.

Authors:  Shang Wan; Yi Wei; Xin Zhang; Xijiao Liu; Weiwei Zhang; Yuhao He; Fang Yuan; Shan Yao; Yufeng Yue; Bin Song
Journal:  Ann Transl Med       Date:  2020-03

4.  The Efficiency of Fractional Anisotropy, Apparent Diffusion Coefficient, and Contrast Enhancement Index in Liver Fibrosis Staging.

Authors:  Umut Percem Orhan Soylemez; Deniz Turkyilmaz Mut; Canan Alatas Alkim; Huseyin Alkim; Banu Yılmaz Ozguven; Salih Boga; Muzaffer Basak; Sukru Mehmet Erturk
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2022-03-28

Review 5.  Liver-specific agents for contrast-enhanced MRI: role in oncological imaging.

Authors:  Yee Liang Thian; Angela M Riddell; Dow-Mu Koh
Journal:  Cancer Imaging       Date:  2013-12-30       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.